Tokyo Tape
Sign in
← Fukuda Denshi

Half-year report · Q2

6960.TEDINET S100UR0K
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥64.3bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥140.3bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥66.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥10.7bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥14.0bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥11.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥27.0bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥14.1bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥11.4bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥14.3bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥7.7bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥18.7bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥9.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥7.7bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥9.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥204.8bnat 2024-09-30Cons.Assets
Total assets¥209.1bnat 2024-03-31Cons.Assets
Total assets¥210.8bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥32.8bnat 2024-09-30Cons.Liabilities
Total liabilities¥40.1bnat 2024-03-31Cons.Liabilities
Net assets / equity¥172.0bnat 2024-09-30Cons.Net assets
Net assets / equity¥169.0bnat 2024-03-31Cons.Net assets
Net assets / equity¥171.5bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥64.2bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥60.2bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥61.2bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥57.2bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥67.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥64.9bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥14.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥23.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥10.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥14.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥4.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥17.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥267.342024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥622.442023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥324.322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio84.0%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio80.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio81.3%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥17.8bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥17.8bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentsegment profit2024-04-01 → 2024-09-30¥2.6bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue2024-04-01 → 2024-09-30¥30.5bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue external2024-04-01 → 2024-09-30¥30.5bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentsegment profit2024-04-01 → 2024-09-30¥5.6bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue2024-04-01 → 2024-09-30¥4.1bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue external2024-04-01 → 2024-09-30¥4.1bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentsegment profit2024-04-01 → 2024-09-30¥658m
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue2024-04-01 → 2024-09-30¥11.9bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue external2024-04-01 → 2024-09-30¥11.9bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥64.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥64.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥10.7bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.1bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue2023-04-01 → 2023-09-30¥29.3bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue external2023-04-01 → 2023-09-30¥29.3bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue external2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentsegment profit2023-04-01 → 2023-09-30¥737m
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥66.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥66.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥14.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 514
ItemContextValueUnit
Capital stockPrior1YearInstant4621000000JPY
Capital stockCurrentQuarterInstant4621000000JPY
Capital surplusPrior1YearInstant17506000000JPY
Capital surplusCurrentQuarterInstant17506000000JPY
Retained earningsPrior1YearInstant167359000000JPY
Retained earningsCurrentQuarterInstant172012000000JPY
Treasury stockPrior1YearInstant-27266000000JPY
Treasury stockCurrentQuarterInstant-27260000000JPY
Shareholders equityPrior1YearInstant162220000000JPY
Shareholders equityCurrentQuarterInstant166880000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant5594000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant4074000000JPY
Foreign currency translation adjustmentPrior1YearInstant578000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant470000000JPY
Remeasurements of defined benefit plansPrior1YearInstant613000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant550000000JPY
Valuation and translation adjustmentsPrior1YearInstant6787000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant5095000000JPY
Net assetsPrior1YearInstant169008000000JPY
Net assetsCurrentQuarterInstant171975000000JPY
Liabilities and net assetsPrior1YearInstant209064000000JPY
Liabilities and net assetsCurrentQuarterInstant204776000000JPY
Net salesPrior1YTDDuration66541000000JPY
Net salesCurrentYTDDuration64314000000JPY
Cost of salesPrior1YTDDuration29533000000JPY
Cost of salesCurrentYTDDuration30533000000JPY
Gross profitPrior1YTDDuration37007000000JPY
Gross profitCurrentYTDDuration33780000000JPY
Selling general and administrative expensesPrior1YTDDuration23055000000JPY
Selling general and administrative expensesCurrentYTDDuration23125000000JPY
Operating incomePrior1YTDDuration13951000000JPY
Operating incomeCurrentYTDDuration10654000000JPY
Interest income noiPrior1YTDDuration44000000JPY
Interest income noiCurrentYTDDuration46000000JPY
Dividends income noiPrior1YTDDuration110000000JPY
Dividends income noiCurrentYTDDuration125000000JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration77000000JPY
Gain on investments in partnership noiPrior1YTDDuration1000000JPY
Gain on investments in partnership noiCurrentYTDDuration78000000JPY
Insurance income noiPrior1YTDDuration9000000JPY
Insurance income noiCurrentYTDDuration150000000JPY
Other noiPrior1YTDDuration81000000JPY
Other noiCurrentYTDDuration159000000JPY
Non operating incomePrior1YTDDuration247000000JPY
Non operating incomeCurrentYTDDuration637000000JPY
Interest expenses noePrior1YTDDuration16000000JPY
Interest expenses noeCurrentYTDDuration20000000JPY
Foreign exchange losses noePrior1YTDDuration68000000JPY
Foreign exchange losses noeCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass